Table Info

Table 1.

Demography, clinical and molecular characteristics of MB

Subgroup		WNT		SHH				Non-WNT/non-SHH group 3			Non-WNT/non-SHH group 4
Subtype		WNT	WNT	SHH	SHH	SHH	SHH	Group	Group	Group	Group	Group	Group
Subtype		α	β	α	β	γ	δ	3α	3β	3γ	4α	4β	4γ
Demography and clinical features	Age at diagnosis (years, median)	10	20	8	1.9	1.33	26	4.82	7.55	5	8.22	10	7
	Subtype proportion (%)	70	30	29.1	15.7	21.1	34.1	46.5	25.7	27.8	30.1	33.4	36.5
	Metastases (%)	8.6	21.4	20	33	8.9	9.4	43.4	20	39.4	40	40.7	38.7
	Survival rate (5 years, %)	97	100	69.8	67.3	88	88.5	66.2	55.8	41.9	66.8	75.4	82.5
Molecular features	Gene mutation	CTNNB1, TP53, DDX3X, MLL2/3		PTCH1, SMO, SUFU, TP53, DDX3X, CREBBP, MLL2/3, TERT, KDM6A				TERT, KDM6A			TERT, KDM6A
	Gene modification	TNRC6C methy		TNRC6C methy, MXI1 methy, IL8 methy				TNRC6C methy, MXI1 methy, IL8 methy			TNRC6C methy, MXI1 methy, IL8 methy, Lmx1A enhancer activation, PRDM6 induction
	Copy number variation	OTX2 amp, CDK6 amp		MYCN amp, CDK6 amp, PTEN loss, GLI2 amp				MYC amp, OTX2 amp, CDK6 amp, KDM6A loss, KBTBD4 insertion			MYCN amp, OTX2 amp, CDK6 amp, PTEN loss, KDM6A loss, KBTBD4 insertion
	miRNA profile	miR-183, miR-206		miR-206				miR-592, miR-182, miR-193a, miR-183, miR-206			miR-592, miR-182, miR-183, miR-206
	Other events	-		-				GFI1/GFI1B activation, MYC acetylation, and phosphorylation			GFI1/GFI1B activation, ERBB4-SRC activation
Potential targeted drugs		WNT/β-catenin inhibitor		SMO inhibitor, GLI inhibitor, PI3K inhibitor, CDK4/6 inhibitor				CDK4/6 inhibitor, MYC inhibitor			CDK4/6 inhibitor

amp: amplification; CDK6: cyclin-dependent kinases 6; CREBBP: cAMP-response element binding protein (CREB)-binding protein; CTNNB1: cadherin-associated protein beta 1; DDX3X: DEAD-box helicase 3 X-linked; ERBB4-SRC: Erb-b2 receptor tyrosine kinase 4 (ERBB4)-proto-oncogene tyrosine-protein kinase SRC (SRC); GFI1: growth factor independent 1; GLI2: glioma-associated oncogene homolog 2; IL8: interleukin 8; KBTBD4: Kelch repeat and broad-complex, tramtrack, and bric-a-brac domain containing 4; KDM6A: lysine-specific demethylase 6A; Lmx1A: LIM homeobox transcription factor 1, alpha; methy: methylation; miRNA: microRNA; MLL2/3: mixed-lineage leukemia 2/3; MXI1: max interactor 1; MYC: myelocytomatosis oncogene; MYCN: neuroblastoma derived MYC; OTX2: orthodenticle homeobox 2; PI3K: phosphatidylinositol 3-kinase; PRDM6: PR/SET domain 6; PTCH1: patched 1; PTEN: phosphatase and tensin homolog; SMO: smoothened; SUFU: suppressor of fused; TERT: telomerase reverse transcriptase; TNRC6C: trinucleotide repeat containing 6C; -: blank cell

Declarations

Author contributions

ZZ: Investigation, Writing—original draft. BZ: Investigation. QM: Writing—review & editing. TZ: Funding, Data curation. YW: Data curation. RY: Supervision, Funding, Writing—review & editing. SG: Conceptualization, Funding, Supervision, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by National Natural Science Foundation of China (Nos. 82002632 and 82072763) and the Key Research & Development Plan of Xuzhou City (Nos. KC20076 and KC21183). S. Gao was supported by the Jiangsu Provincial Six Talents Peak (2019-SWYY-092). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro Oncol. 1999;1:232–50. [DOI] [PubMed] [PMC]

Ramaswamy V, Taylor MD. Medulloblastoma: from myth to molecular. J Clin Oncol. 2017;35:2355–63. [DOI] [PubMed]

Brandes AA, Bartolotti M, Marucci G, Ghimenton C, Agati R, Fioravanti A, et al. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Crit Rev Oncol Hematol. 2015;94:348–59. [DOI] [PubMed]

Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19:1541–4. [DOI] [PubMed]

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. [DOI] [PubMed] [PMC]

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. [DOI] [PubMed]

Kijima N, Kanemura Y. Molecular classification of medulloblastoma. Neurol Med Chir (Tokyo). 2016;56:687–97. [DOI] [PubMed] [PMC]

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. [DOI] [PubMed] [PMC]

Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465–72. [DOI] [PubMed] [PMC]

10.

Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 2014;510:537–41. [DOI] [PubMed]

11.

Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31:737–54. [DOI] [PubMed] [PMC]

12.

Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017;18:958–71. [DOI] [PubMed]

13.

Khatua S, Song A, Citla Sridhar D, Mack SC. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights. Curr Neuropharmacol. 2018;16:1045–58. [DOI] [PubMed] [PMC]

14.

Cordeiro BM, Oliveira ID, Alves MT, Saba-Silva N, Capellano AM, Cavalheiro S, et al. SHH, WNT, and NOTCH pathways in medulloblastoma: when cancer stem cells maintain self-renewal and differentiation properties. Childs Nerv Syst. 2014;7:1165–72. [DOI] [PubMed]

15.

Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 1998;58:896–9. [PubMed]

16.

Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–96. [DOI] [PubMed] [PMC]

17.

Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488:100–5. [DOI] [PubMed] [PMC]

18.

Silva Rd, Marie SK, Uno M, Matushita H, Wakamatsu A, Rosemberg S, et al. CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants. Clinics (Sao Paulo). 2013;68:167–72. [DOI] [PubMed]

19.

Goschzik T, Zur Mühlen A, Kristiansen G, Haberler C, Stefanits H, Friedrich C, et al. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. Neuropathol Appl Neurobiol. 2015;41:135–44. [DOI] [PubMed]

20.

Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–31. [DOI] [PubMed]

21.

Cambruzzi E. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. Childs Nerv Syst. 2018;34:809–15. [DOI] [PubMed]

22.

Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother. 2012;12:871–84. [DOI] [PubMed] [PMC]

23.

Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25:393–405. [DOI] [PubMed] [PMC]

24.

Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59–71. [DOI] [PubMed] [PMC]

25.

Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547:311–17. [DOI] [PubMed] [PMC]

26.

Wong GC, Li KK, Wang WW, Liu AP, Huang QJ, Chan AK, et al. Clinical and mutational profiles of adult medulloblastoma groups. Acta Neuropathol Commun. 2020;8:191. [DOI] [PubMed] [PMC]

27.

Šoukalová J, Vejmělková K, Cermanová T, Kašíková K, Mikulášová A, Janyšková H, et al. Identification of a family with SUFU germline deletion based on a case of desmoplastic medulloblastoma in an infant. Klin Onkol. 2016;29:S83–8. Czech; [DOI] [PubMed]

28.

Guerrini-Rousseau L, Dufour C, Varlet P, Masliah-Planchon J, Bourdeaut F, Guillaud-Bataille M, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol. 2018;20:1122–32. [DOI] [PubMed] [PMC]

29.

Ramaswamy V, Nör C, Taylor MD. Erratum: p53 and meduloblastoma. Cold Spring Harb Perspect Med. 2015;6:a029579. [DOI] [PubMed] [PMC]

30.

Ongürü O, Karslioglu Y, Ozcan A, Celik E. Anti-apoptotic and growth-promoting markers in adult medulloblastomas. Clin Neuropathol. 2010;29:384–9. [DOI] [PubMed]

31.

Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol. 2010;28:1345–50. [DOI] [PubMed]

32.

Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31:2927–35. [DOI] [PubMed] [PMC]

33.

Rosner A, Rinkevich B. The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays. Curr Med Chem. 2007;14:2517–25. [DOI] [PubMed]

34.

Linder P. Dead-box proteins: a family affair—active and passive players in RNP-remodeling. Nucleic Acids Res. 2006;34:4168–80. [DOI] [PubMed] [PMC]

35.

Tanner NK, Linder P. DExD/H box RNA helicases: from generic motors to specific dissociation functions. Mol Cell. 2001;8:251–62. [DOI] [PubMed]

36.

He Y, Zhang D, Yang Y, Wang X, Zhao X, Zhang P, et al. A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression (review). Oncol Rep. 2018;39:883–92. [DOI] [PubMed]

37.

Li HK, Mai RT, Huang HD, Chou CH, Chang YA, Chang YW, et al. DDX3 represses stemness by epigenetically modulating tumor-suppressive miRNAs in hepatocellular carcinoma. Sci Rep. 2016;6:28637. [DOI] [PubMed] [PMC]

38.

Bol GM, Raman V, van der Groep P, Vermeulen JF, Patel AH, van der Wall E, et al. Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer. PLoS One. 2013;8:e63548. [DOI] [PubMed] [PMC]

39.

Heerma van Voss MR, Schrijver WAME, ter Hoeve ND, Hoefnagel LD, Manson QF, van der Wall E, et al. The prognostic effect of DDX3 upregulation in distant breast cancer metastases. Clin Exp Metastasis. 2017;34:85–92. [DOI] [PubMed] [PMC]

40.

Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488:43–8. [DOI] [PubMed] [PMC]

41.

Patmore DM, Jassim A, Nathan E, Gilbertson RJ, Tahan D, Hoffmann N, et al. DDX3X suppresses the susceptibility of hindbrain lineages to medulloblastoma. Dev Cell. 2020;54:455–70. [DOI] [PubMed] [PMC]

42.

Merk DJ, Ohli J, Merk ND, Thatikonda V, Morrissy S, Schoof M, et al. Opposing effects of CREBBP mutations govern the phenotype of Rubinstein-Taybi syndrome and adult SHH medulloblastoma. Dev Cell. 2018;44:709–24. [DOI] [PubMed]

43.

Li Y, Song Q, Day BW. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Acta Neuropathol Commun. 2019;7:123. [DOI] [PubMed] [PMC]

44.

Ichimura K, Nishikawa R, Matsutani M. Molecular markers in pediatric neuro-oncology. Neuro Oncol. 2012;14:iv90–9. [DOI] [PubMed] [PMC]

45.

Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331:435–39. [DOI] [PubMed] [PMC]

46.

Patel B, Taiwo R, Kim AH, Dunn GP. TERT, a promoter of CNS malignancies. Neurooncol Adv. 2020;2:1–11. [DOI] [PubMed] [PMC]

47.

Remke M, Ramaswamy V, Peacock J, Shih DJH, Koelsche C, Northcott PA, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013;126:917–29. [DOI] [PubMed] [PMC]

48.

Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of group 3 and group 4 subtypes. Acta Neuropathol. 2019;138:309–26. [DOI] [PubMed] [PMC]

49.

Menyhárt O, Giangaspero F Győrffy B. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. J Hematol Oncol. 2019;12:29. [DOI] [PubMed] [PMC]

50.

Roussel MF, Robinson GW. Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. 2013;3:1–15. [DOI] [PubMed] [PMC]

51.

Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488:49–56. [DOI] [PubMed] [PMC]

52.

Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123:501–13. [DOI] [PubMed]

53.

Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5:11. [DOI] [PubMed]

54.

Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012;123:515–27. [DOI] [PubMed]

55.

Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010;24:1059–72. [DOI] [PubMed] [PMC]

56.

Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol. 2012;123:473–84. [DOI] [PubMed] [PMC]

57.

Shih DJ, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32:886–96. [DOI] [PubMed] [PMC]

58.

Beby F, Lamonerie T. The homeobox gene Otx2 in development and disease. Exp Eye Res. 2013;111:9–16. [DOI] [PubMed]

59.

Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res. 2005;65:703–7. [DOI] [PubMed]

60.

Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3:e3088. [DOI] [PubMed] [PMC]

61.

Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14. [DOI] [PubMed] [PMC]

62.

Lu Y, Labak CM, Jain N, Purvis IJ, Guda MR, Bach SE, et al. OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma. Am J Cancer Res. 2017;7:647–56. [PubMed] [PMC]

63.

Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, et al. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Int J Cancer. 2012;131:E21–32. [DOI] [PubMed]

64.

Bunt J, de Haas TG, Hasselt NE, Zwijnenburg DA, Koster J, Versteeg R, et al. Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. Mol Cancer Res. 2010;8:1344–57. [DOI] [PubMed]

65.

Zhao F, Ohgaki H, Xu L, Giangaspero F, Li C, Li P, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016;18:982–90. [DOI] [PubMed] [PMC]

66.

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–72. [DOI] [PubMed]

67.

Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005;23:8853–62. [DOI] [PubMed]

68.

Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007;3:682–93. [DOI] [PubMed]

69.

Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, et al. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One. 2010;5:e10849. [DOI] [PubMed] [PMC]

70.

da Silva LS, Mancano BM, de Paula FE, Dos Reis MB, de Almeida GC, Matsushita M, et al. Expression of GNAS, TP53, and PTEN improves the patient prognostication in sonic hedgehog (SHH) medulloblastoma subgroup. J Mol Diagn. 2020;22:957–66. [DOI] [PubMed]

71.

Gažová I, Lengeling A, Summers KM. Lysine demethylases KDM6A and UTY: the X and Y of histone demethylation. Mol Genet and Metab. 2019;127:31–44. [DOI] [PubMed]

72.

Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2013;125:373–84. [DOI] [PubMed] [PMC]

73.

Yi J, Shi X, Xuan Z, Wu J. Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma. Cancer Lett. 2021;499:188–200. [DOI] [PubMed] [PMC]

74.

Leal LF, Cavagna RO, Campanella NC, Mançano B, Almeida GC, Matsushita M, et al. Lack of KBTBD4 mutations in molecularly classified Brazilian medulloblastomas. J Neuropathol Exp Neurol. 2019;78:788–90. [DOI] [PubMed]

75.

Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14:416–29. [DOI] [PubMed]

76.

Zhang J, Tian XJ, Xing J. Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks. J Clin Med. 2016;5:41. [DOI] [PubMed] [PMC]

77.

Lee RT, Zhao Z, Ingham PW. Hedgehog signalling. Development. 2016;143:367–72. [DOI] [PubMed]

78.

Infante P, Faedda R, Bernardi F, Bufalieri F, Lospinoso Severini L, Alfonsi R, et al. Itch/β-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. Nat Commun. 2018;9:976. [DOI] [PubMed] [PMC]

79.

Kogerman P, Grimm T, Kogerman L, Krause D, Undén AB, Sandstedt B, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat Cell Biol. 1999;1:312–9. [DOI] [PubMed]

80.

Lospinoso Severini L, Ghirga F, Bufalieri F, Quaglio D, Infante P, Di Marcotullio L. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma. Expert Opin Ther Targets. 2020;24:1159–81. [DOI] [PubMed]

81.

Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012;21:374–87. [DOI] [PubMed] [PMC]

82.

Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12:818–34. [DOI] [PubMed] [PMC]

83.

Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20:21–37. [DOI] [PubMed] [PMC]

84.

Li J, Zhao S, Lee M, Yin Y, Li J, Zhou Y, et al. Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma. Sci Adv. 2020;6:eabb5427. [DOI] [PubMed] [PMC]

85.

Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell. 1993;72:223–32. [DOI] [PubMed]

86.

Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128:2038–49. [DOI] [PubMed] [PMC]

87.

Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 2013;125:359–71. [DOI] [PubMed] [PMC]

88.

Chizhikov VV, Lindgren AG, Mishima Y, Roberts RW, Aldinger KA, Miesegaes GR, et al. Lmx1a regulates fates and location of cells originating from the cerebellar rhombic lip and telencephalic cortical hem. Proc Natl Acad Sci U S A. 2010;107:10725–30. [DOI] [PubMed] [PMC]

89.

Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature. 2016;530:57–62. [DOI] [PubMed] [PMC]

90.

Gewies A, Castineiras-Vilarino M, Ferch U, Jährling N, Heinrich K, Hoeckendorf U, et al. Prdm6 is essential for cardiovascular development in vivo. PLoS One. 2013;8:e81833. [DOI] [PubMed] [PMC]

91.

Saleque S, Cameron S, Orkin SH. The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev. 2002;16:301–6. [DOI] [PubMed] [PMC]

92.

Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511:428–34. [DOI] [PubMed] [PMC]

93.

Segers VFM, Dugaucquier L, Feyen E, Shakeri H, De Keulenaer GW. The role of ErbB4 in cancer. Cell Oncol (Dordr). 2020;43:335–52. [DOI] [PubMed]

94.

Forget A, Martignetti L, Puget S, Calzone L, Brabetz S, Picard D, et al. Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell. 2018;34:379–95. [DOI] [PubMed]

95.

Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424–30. [DOI] [PubMed] [PMC]

96.

Archer TC, Ehrenberger T, Mundt F, Gold MP, Krug K, Mah CK, et al. Proteomics, post-translational modifications, and integrative analyses reveal molecular heterogeneity within medulloblastoma subgroups. Cancer Cell. 2018;34:396–410. [DOI] [PubMed] [PMC]

97.

Song Y, Li C, Jin L, Xing J, Sha Z, Zhang T, et al. RIOK2 is negatively regulated by miR-4744 and promotes glioma cell migration/invasion through epithelial-mesenchymal transition. J Cell Mol Med. 2020;24:4494–509. [DOI] [PubMed] [PMC]

98.

Pang JC, Kwok WK, Chen Z, Ng HK. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol. 2009;117:599–611. [DOI] [PubMed]

99.

Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, et al. Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol. 2013;15:83–90. [DOI] [PubMed] [PMC]

100.

Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol. 2008;90:1–7. [DOI] [PubMed]

101.

Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol. 2013;15:1644–51. [DOI] [PubMed] [PMC]

102.

Panwalkar P, Moiyadi A, Goel A, Shetty P, Goel N, Sridhar E, et al. MiR-206, a cerebellum enriched miRNA is downregulated in all medulloblastoma subgroups and its overexpression is necessary for growth inhibition of medulloblastoma cells. J Mol Neurosci. 2015;56:673–80. [DOI] [PubMed]

103.

Bharambe HS, Joshi A, Yogi K, Kazi S, Shirsat NV. Restoration of miR-193a expression is tumor-suppressive in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun. 2020;8:70. [DOI] [PubMed] [PMC]

104.

Bai AHC, Milde T, Remke M, Rolli CG, Hielscher T, Cho YJ, et al. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2011;123:529–38. [DOI] [PubMed]

105.

Mollashahi B, Aghamaleki FS, Movafagh A. The roles of miRNAs in medulloblastoma: a systematic review. J Cancer Prev. 2019;24:79–90. [DOI] [PubMed] [PMC]

106.

Zurawel RH, Allen C, Chiappa S, Cato W, Biegel J, Cogen P, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27:44–51. [DOI] [PubMed]

107.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Onco. 2015;33:2646–54. [DOI] [PubMed] [PMC]

108.

Lin Z, Li S, Sheng H, Cai M, Ma LY, Hu L, et al. Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis. J Cancer Res Clin Oncol. 2016;142:2469–78. [DOI] [PubMed] [PMC]

109.

Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011;121:148–60. [DOI] [PubMed] [PMC]

110.

Jynho Kim, Lee JJ, James Kim, Gardner D, Beachy PA. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107:13432–7. [DOI] [PubMed] [PMC]

111.

Di Magno L, Manzi D, D’Amico D, Coni S, Macone A, Infante P, et al. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. Cell Cycle. 2014;13:3404–13. [DOI] [PubMed] [PMC]

112.

Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As₂O₃) in the treatment of acute promyelocytic leukemia: As₂O₃ induces NB₄ cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood. 1996;88:1052–61. [DOI] [PubMed]

113.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34. [DOI] [PubMed] [PMC]

114.

Holzhauser S, Lukoseviciute M, Andonova T, Ursu RG, Dalianis T, Wickström M, et al. Targeting fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) signaling pathways in medulloblastoma cell lines. Anticancer Res. 2020;40:53–66. [DOI] [PubMed]

115.

Chaturvedi NK, Kling MJ, Coulter DW, McGuire TR, Ray S, Kesherwani V, et al. Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. Oncotarget. 2018;9:16619–33. [DOI] [PubMed] [PMC]

116.

Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, et al. Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation phase 1 trial. EBioMedicine. 2017;23:79–87. [DOI] [PubMed] [PMC]

117.

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, et al. Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell. 2016;29:508–22. [DOI] [PubMed] [PMC]

118.

Cook Sangar ML, Genovesi LA, Nakamoto MW, Davis MJ, Knobluagh SE, Ji P, et al. Inhibition of CDK4/6 by palbociclib significantly extends survival in medulloblastoma patient-derived xenograft mouse models. Clin Cancer Res. 2017;23:5802–13. [DOI] [PubMed] [PMC]

119.

Van Mater D, Gururangan S, Becher O, Campagne O, Leary S, Phillips JJ, et al. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: a pediatric brain tumor consortium study (PBTC-042). Pediatr Blood Cancer. 2021;68:e28879. [DOI] [PubMed] [PMC]

120.

Daggubati V, Hochstelter J, Bommireddy A, Choudhury A, Krup AL, Kaur P, et al. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models. J Clin Invest. 2021;131:e141171. [DOI] [PubMed] [PMC]

121.

Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20:912–25. [DOI] [PubMed] [PMC]

122.

Venkataraman S, Alimova I, Balakrishnan I, Harris P, Birks DK, Griesinger A, et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014;5:2355–71. [DOI] [PubMed] [PMC]

123.

Vinod Kumar, Virender Kumar, McGuire T, Coulter DW, Sharp JG, Mahato RI. Challenges and recent advances in medulloblastoma therapy. Trends Pharmacol Sci. 2017;38:1061–84. [DOI] [PubMed]